Top news from MedWatch this week
Monday
Novo Nordisk’s acquisition journey is driven by price pressure and a hunger for innovation
Potential success could be head-scratcher for Novo Nordisk chair
Novo Holdings beats record as value of assets exceeds EUR 90bn
Demant to release quarterly figures from May onwards
Tuesday
CEO van de Winkel wants long tenure at Genmab
Novo Nordisk gets 2.0 mg Ozempic dose approved in US
Wednesday
Restructuring gives embattled Orphazyme three paths to survival
Zealand Pharma appoints head of R&D as CEO
New FDA requirements could provide opportunities for Genmab, CEO says
Thursday
Genmab CEO says Janssen should ”show respect” as royalty strife nears conclusion
Newly appointed Zealand Pharma CEO says commercial organization was too expensive
Friday
Orphazyme is in dialog with a number of potential suitors in search of rescue
Orphazyme’s creditors left without real options
Orphazyme reveals survival plan: Possible buyers and investors have been contacted
GN Hearing CEO: OTC will increase price transparency on the hearing market
Head of US audiologist association thinks OTC could increase hearing loss awareness
